Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.

Related Articles

Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.

Trends Mol Med. 2017 Nov 10;:

Authors: Cifaldi L, Locatelli F, Marasco E, Moretta L, Pistoia V

Abstract
Natural killer (NK) cells efficiently recognize and kill tumor cells through several mechanisms including the expression of ligands for NK cell-activating receptors on target cells. Different clinical trials indicate that NK cell-based immunotherapy represents a promising antitumor treatment. However, tumors develop immune-evasion strategies, including downregulation of ligands for NK cell-activating receptors, that can negatively affect antitumor activity of NK cells, which either reside endogenously, or are adoptively transferred. Thus, restoration of the expression of NK cell-activating ligands on tumor cells represents a strategic therapeutic goal. As discussed here, various anticancer drugs can fulfill this task via different mechanisms. We envision that the combination of selected chemotherapeutic agents with NK cell adoptive transfer may represent a novel strategy for cancer immunotherapy.

PMID: 29133133 [PubMed - as supplied by publisher]

http://ift.tt/2AKWL7b